Tous Actualités
Suivre
Abonner Medicsight Inc.

Medicsight Inc.

Medicsight Inc. Files American Stock Exchange Application, Appoints Three Independent Directors, Establishes Audit Committee

London (ots/PRNewswire)

Medicsight Inc. (OTC Bulletin Board:
MSHT) announced today that on November 30, 2004 it forwarded its
application to transfer the Company's listing from the OTC Bulletin
Board to the American Stock Exchange to Cohen Specialists LLC, who
deposited it with the American Stock Exchange on December 6, 2004.
New Directors
It was also announced that the Company has appointed three
independent directors, Sir Christopher Paine, Peter Venton and Neal
Wyman, to its Board of Directors.
Sir Christopher Paine and Peter Venton are independent directors
of Medicsight Inc.'s majority owned subsidiary Medicsight PLC.
Neal Wyman trained as a chartered accountant (ACA) with Coopers
and Lybrand before moving to KPMG where he worked in the Far East. He
moved into the recruitment industry in London specialising in
financial services, gaining experience with a diverse range of
clients. He entered executive search in 1981, initially specialising
in the financial services industry before broadening into general
appointments and professional services. He now focuses on general
management, finance and non-executive appointments in both private
and quoted companies, with particular focus on venture capital. He is
a graduate of the London School of Economics.
Audit Committee
On November 25, 2004 the Board of Directors of Medicsight, Inc.
established an Audit Committee and adopted the Audit Committee
Charter. The Board also adopted the Company's Code of Ethics.
Subsequently Neal Wyman, Peter Venton and Professor Nadey Hakim,
all being independent directors, were appointed to serve on the Audit
Committee. The Audit Committee had their first meeting on November
26, 2004 and approved both the Audit Committee Charter and the
Company's Code of Ethics.
Neal Wyman will chair the Audit Committee and the Company can
certify that Mr. Wyman fulfills the requirements for a member of the
Audit Committee to be financially sophisticated.
About Medicsight
Medicsight is a software development business focused on the
medical imaging market. The company is using its core technology to
develop automatic detection and analytical tools for clinicians to
improve their ability to diagnose and treat disease, initially
focusing on three key clinical areas -- lung cancer, colon cancer,
and coronary heart disease. Medicsight's software will enable earlier
and more accurate detection and treatment of suspicious lesions,
which can save lives and reduce healthcare costs. Headquartered in
London, Medicsight employs more than 60 people and has offices in the
U.K., United States, and China. Product and company information can
be found on http://www.medicsight.com . Stock symbol: OTCBB: MSHT
All forward-looking statements are made pursuant to the 'safe
harbor' provisions of the Private Securities litigation Reform Act of
1995. Forward-looking statements are based on current management
expectations that involve risks and uncertainties that may result in
such expectations not being realized. Potential risks and
uncertainties include, but are not limited to, the risks described in
company filings with the Securities and Exchange Commission.
Web site: http://www.medicsight.com

Contact:

James Whale of Medicsight, +44-20-7598-4070, info@medicsight.com

Plus de actualités: Medicsight Inc.
Plus de actualités: Medicsight Inc.